Accelerate Diagnostics (AXDX) has released preliminary, unaudited results for Q4 and full-year 2024. The company reported preliminary revenue of approximately $11.7 million for the year, compared to $12.1 million in 2023. While consumable product revenues increased by 3%, overall revenue declined due to lower Pheno instrument capital sales.